These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19597027)

  • 1. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
    J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of axitinib in advanced neuroendocrine tumors.
    Strosberg JR; Cives M; Hwang J; Weber T; Nickerson M; Atreya CE; Venook A; Kelley RK; Valone T; Morse B; Coppola D; Bergsland EK
    Endocr Relat Cancer; 2016 May; 23(5):411-8. PubMed ID: 27080472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
    Cohen EE; Tortorici M; Kim S; Ingrosso A; Pithavala YK; Bycott P
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1261-70. PubMed ID: 25315258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axitinib for the management of metastatic renal cell carcinoma.
    Escudier B; Gore M
    Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.
    Michael M; Vlahovic G; Khamly K; Pierce KJ; Guo F; Olszanski AJ
    Br J Cancer; 2010 Nov; 103(10):1554-61. PubMed ID: 20959830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial.
    Park JO; Feng YH; Su WC; Oh DY; Keam B; Shen L; Kim SW; Liu X; Liao H; Qing M; Zhang C; Qian J; Tang X; Li P; Triantos S; Sweiti H
    BMC Cancer; 2024 Aug; 24(1):1006. PubMed ID: 39138436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study.
    Oya M; Tomita Y; Fukasawa S; Shinohara N; Habuchi T; Rini BI; Fujii Y; Kamei Y; Umeyama Y; Bair AH; Uemura H
    Cancer Sci; 2017 Jun; 108(6):1231-1239. PubMed ID: 28267243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients.
    Mukohara T; Nakajima H; Mukai H; Nagai S; Itoh K; Umeyama Y; Hashimoto J; Minami H
    Cancer Sci; 2010 Apr; 101(4):963-8. PubMed ID: 20180805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
    Algazi AP; Cha E; Ortiz-Urda SM; McCalmont T; Bastian BC; Hwang J; Pampaloni MH; Behr S; Chong K; Cortez B; Quiroz A; Coakley F; Liu S; Daud AI
    Br J Cancer; 2015 Apr; 112(8):1326-31. PubMed ID: 25867272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
    Gauler TC; Besse B; Mauguen A; Meric JB; Gounant V; Fischer B; Overbeck TR; Krissel H; Laurent D; Tiainen M; Commo F; Soria JC; Eberhardt WEE
    Ann Oncol; 2012 Mar; 23(3):678-687. PubMed ID: 21617019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
    Ferrarotto R; Sousa LG; Feng L; Mott F; Blumenschein G; Altan M; Bell D; Bonini F; Li K; Marques-Piubelli ML; Dal Lago EA; Johnson JJ; Mitani Y; Godoy M; Lee A; Kupferman M; Hanna E; Glisson BS; Elamin Y; El-Naggar A
    J Clin Oncol; 2023 May; 41(15):2843-2851. PubMed ID: 36898078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer.
    Auberle C; Gao F; Sloan M; Morgensztern D; Winkler L; Ward JP; Devarakonda S; Rearden TP; Govindan R; Waqar SN
    J Thorac Dis; 2024 Jun; 16(6):3782-3793. PubMed ID: 38983151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
    Traynor AM; Dubey S; Eickhoff JC; Kolesar JM; Schell K; Huie MS; Groteluschen DL; Marcotte SM; Hallahan CM; Weeks HR; Wilding G; Espinoza-Delgado I; Schiller JH
    J Thorac Oncol; 2009 Apr; 4(4):522-6. PubMed ID: 19347984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular Endothelial Growth Factor Receptor Inhibitors for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis.
    Hoff CO; Manzi J; Lazar Neto F; Ferrarotto R
    JAMA Otolaryngol Head Neck Surg; 2024 Jul; 150(7):587-597. PubMed ID: 38814585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma.
    Thiebaud JA; Ravi V; Litwin S; Schuetze SM; Movva S; Agulnik M; Kraft AS; Tetzlaff ED; Somaiah N; von Mehren M
    Cancer; 2022 Oct; 128(19):3516-3522. PubMed ID: 35942596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
    Hanna GJ; Ahn MJ; Muzaffar J; Keam B; Bowles DW; Wong DJ; Ho AL; Kim SB; Worden F; Yun T; Meng X; Van Tornout JM; Conlan MG; Kang H
    Clin Cancer Res; 2023 Nov; 29(22):4555-4563. PubMed ID: 37643133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of Axitinib and Sorafenib treatment in glioblastoma cell viability and morphology.
    Opriţa A; Dobrescu MA; Manea EV; Popescu ŞO; Sevastre AS; Pîrvu AS; Buzatu IM; Tache DE
    Rom J Morphol Embryol; 2023; 64(2):173-180. PubMed ID: 37518874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.
    Hillman GG; Lonardo F; Hoogstra DJ; Rakowski J; Yunker CK; Joiner MC; Dyson G; Gadgeel S; Singh-Gupta V
    Transl Oncol; 2014 May; 7(3):400-9. PubMed ID: 24862536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1-resistant mucosal melanoma.
    Lochrin SE; Cugliari MK; Yeh R; Shoushtari AN
    Melanoma Res; 2024 Oct; 34(5):450-456. PubMed ID: 38953532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors.
    Li D; Chen C; Li J; Yue J; Ding Y; Wang H; Liang Z; Zhang L; Qiu S; Liu G; Gao Y; Huang Y; Li D; Zhang R; Liu W; Wen X; Li B; Zhang X; Zhang X; Xu RH
    Nat Commun; 2023 Jun; 14(1):3447. PubMed ID: 37301885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.